Vectus Biosystems (ASX:VBS) Other Current Payables: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:VBS Vectus Biosystems Ltd ASX:VBS
15 GF Score
Price A$0.20
! 2 Warning Signs
View Full Analysis

What is Vectus Biosystems Other Current Payables?

Vectus Biosystems ASX:VBS +14.29% 15 Other Current Payables is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:VBS with a GF Score™ of 15/100. The stock has 2 warning signs investors should review.

Vectus Biosystems's Other Current Payables for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Vectus Biosystems's quarterly Other Current Payables increased from Dec. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.00 Mil) but then declined from Jun. 2025 (A$0.00 Mil) to Dec. 2025 (A$0.00 Mil).

Vectus Biosystems's annual Other Current Payables declined from Jun. 2023 (A$0.03 Mil) to Jun. 2024 (A$0.03 Mil) and declined from Jun. 2024 (A$0.03 Mil) to Jun. 2025 (A$0.00 Mil).

Vectus Biosystems Other Current Payables Related Terms

Vectus Biosystems Other Current Payables Historical Data

* Premium members only.

The historical data trend for Vectus Biosystems's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vectus Biosystems Other Current Payables Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.03 0.03 0.03 0.00

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.03 0.00 0.00 0.00
ASX:VBS
15GF Score
Vectus Biosystems Ltd ASX:VBS
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vectus Biosystems Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of A$0.00 Mil mean?
Vectus Biosystems (ASX:VBS) has a Other Current Payables of A$0.00 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Vectus Biosystems and its competitors.
Is Vectus Biosystems' Other Current Payables too high?
Vectus Biosystems' current Other Current Payables is A$0.00 Mil. Overall, Vectus Biosystems has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Vectus Biosystems' Other Current Payables compare to VRTX and REGN?
Vectus Biosystems' Other Current Payables of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Vectus Biosystems and its competitors. Vectus Biosystems's current Other Current Payables is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectus Biosystems stock overvalued right now?
Vectus Biosystems (ASX:VBS) has a current Other Current Payables of A$0.00 Mil. The current Other Current Payables is A$0.00 Mil. Vectus Biosystems' overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Vectus Biosystems (ASX:VBS), the current Other Current Payables is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vectus Biosystems Business Description

Address 26-34 Dunning Avenue, Unit 5, Ground Floor, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
15GF Score

Get the complete analysis for ASX:VBS

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.20
Price